Abstract
Ovarian cancer is an “intraperitoneal disease” by itself. When first standard treatment fails, usually, the disease is characterized by poor prognosis. Encouraging results have been reported by the treatment of peritoneal carcinomatosis (PC) from epithelial ovarian cancer (EOC) by complete surgical cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). The purpose of this study is to evaluate survival benefit and morbidity of patients with recurrent EOC treated by cytoreductive surgery and HIPEC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
